Twist Bioscience Co. (NASDAQ:TWST) Stake Raised by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 43.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 292,645 shares of the company’s stock after acquiring an additional 89,170 shares during the period. Nuveen Asset Management LLC owned about 0.49% of Twist Bioscience worth $13,599,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of TWST. Barclays PLC increased its position in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares during the last quarter. Blue Trust Inc. increased its position in Twist Bioscience by 19.9% in the 4th quarter. Blue Trust Inc. now owns 4,567 shares of the company’s stock worth $206,000 after purchasing an additional 757 shares during the last quarter. KBC Group NV increased its position in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Twist Bioscience by 11.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,586 shares of the company’s stock worth $585,000 after purchasing an additional 1,318 shares during the last quarter. Finally, Jennison Associates LLC increased its position in Twist Bioscience by 80.2% in the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after purchasing an additional 302,884 shares during the last quarter.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $28.26 on Tuesday. The business has a 50 day moving average price of $36.44 and a 200 day moving average price of $42.69. Twist Bioscience Co. has a twelve month low of $27.12 and a twelve month high of $60.90. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -8.36 and a beta of 2.54. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. This trade represents a 0.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paula Green sold 918 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the sale, the senior vice president now owns 130,912 shares of the company’s stock, valued at $5,355,609.92. This represents a 0.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,011 shares of company stock worth $951,499 in the last 90 days. 3.01% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TWST. Guggenheim reaffirmed a “buy” rating and issued a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. Barclays dropped their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Robert W. Baird lowered their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, The Goldman Sachs Group lowered their price objective on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.